Skip to main content
main-content

Medications

Feature content

12-14-2018 | Sleep apnea | Editorial | Article

Diabetes and obstructive sleep apnea syndrome: Double trouble

Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition.

Author:
John Wilding

11-28-2018 | SGLT2 inhibitors | Commentary | Article

Expert commentary

What can real-world studies really tell us about amputation risk for SGLT2 inhibitors?

John Wilding considers the real-world studies examining the association between SGLT2 inhibitors and amputation risk in patients with type 2 diabetes.

Author:
John Wilding

11-28-2018 | SGLT2 inhibitors | At a glance | Article

Real-world studies of SGLT2 inhibition and amputation risk

How many real-world studies have looked at amputation risk in users of SGLT2 inhibitors, and do the findings support or refute the effect found in CANVAS? medwireNews rounds up the research so far.

11-16-2018 | Dapagliflozin | Feature | Video

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

11-14-2018 | Cardiovascular outcomes | Editorial | Article

What have I learned from cardiovascular outcome trials?

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.

Author:
Sanjay Kalra

11-10-2018 | SGLT2 inhibitors | At a glance | Article

Round-up of the SGLT2 inhibitor CV outcome trials

With DECLARE-TIMI 58 now published, medwireNews rounds up the SGLT2 inhibitor cardiovascular outcome trials so far.

11-10-2018 | Dapagliflozin | Feature | Video

Expert commentary: DECLARE-TIMI 58

Miles Fisher talks to medwireNews about the results of the dapagliflozin cardiovascular outcomes trial DECLARE-TIMI 58.

09-30-2018 | UKPDS | At a glance | Article

What we learned from the UKPDS

The UKPDS has so far generated an astonishing 93 original research papers. medwireNews​​​​​​​ rounds them up.

09-30-2018 | UKPDS | Feature | Article

The UKPDS: A lasting legacy

Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.

09-30-2018 | Glycemic control | Clinical trial summary slides | Collection

10-year follow-up of intensive glucose control in type 2 diabetes

This slide set outlines the results of a 10-year, postinterventional follow-up of the UKPDS survivor cohort which examined whether a continued microvascular benefit from earlier improved glucose control was evident and whether such therapy had a long-term effect on macrovascular outcomes.

09-30-2018 | Medications | Clinical trial summary slides | Collection

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

This slide set outlines the results of the UKPDS33 study which compared the effects of intensive blood-glucose control with either sulfonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes.

09-30-2018 | Metformin | Clinical trial summary slides | Collection

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

This slide set outlines the results of the UKPDS34 study which investigated whether intensive glucose control with metformin had any specific advantage or disadvantage in patients with type 2 diabetes.

09-30-2018 | Hypertension | Clinical trial summary slides | Collection

Long-term follow-up after tight control of blood pressure in type 2 diabetes

This slide set outlines the results of the post-trial monitoring of UKPDS which examined whether risk reductions for microvascular and macrovascular disease, achieved with the use of improved blood-pressure control during the trial, were sustained.

09-30-2018 | Complications | Slideset | Collection

UKPDS clinical trial summary slides

A collection of downloadable PowerPoint slides summarizing the primary and follow-up UKPDS findings. The aim of the UKPDS was to determine the effect of intensive glycemic control on the incidence of complications in patients with type 2 diabetes.

09-26-2018 | Insulin | View from the clinic | Collection

Four steps I take when starting patients on insulin

Editorial Board member Jay Shubrook succinctly delivers his strategies for initiating insulin therapy for the first time in patients with type 2 diabetes.

09-18-2018 | Sexual dysfunction | View from the clinic | Article

Regaining sexual health in diabetes: Start with open communication

Advisory Board member Clipper Young recounts an experience of starting a patient with erectile dysfunction on the path to appropriate treatment for him and his diabetes.

Author:
Clipper Young

09-12-2018 | Diet | Commentary | Article

Diet–drug interactions: Why two rights can make a wrong

Editorial Board member and Endocrinologist, Sanjay Kalra comments on the issues raised by a clinical case involving sodium glucose cotransporter 2 inhibitor therapy alongside a restrictive diet.

Author:
Sanjay Kalra

09-06-2018 | SGLT2 inhibitors | Patient perspective | Article

Living with type 2 diabetes: Patient commentary in response to the paper ‘SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice’

A patient discusses their experience of living with type 2 diabetes, including their experience of diagnosis and self-management, education and adoption of SGLT2 inhibitors to treat the disease.

09-05-2018 | Diagnosis | Case study | Article

Acute illness while on a SGLT2 inhibitor and ketogenic diet

Advisory Board member Theresa Smyth tackles an emergency case in a type 2 diabetes patient treated with empagliflozin. What went wrong and how should he be managed?

Author:
Theresa Smyth

08-01-2018 | Type 2 diabetes | View from the clinic | Audio

Barriers to insulin: Management in type 2 diabetes patients

Editorial Board member Lori Berard discusses how to meet and overcome the challenges that follow the initial insulin prescription in patients with type 2 diabetes (11:53).

image credits